NCT04629495View on ClinicalTrials.gov

Rapamycin - Effects on Alzheimer's and Cognitive Health

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

August 11, 2021

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions
Mild Cognitive ImpairmentAlzheimer Disease
Interventions
DRUG

Rapamycin

RAPA will be administered orally 1mg daily

OTHER

Placebo

Placebo will be administered orally once daily

Trial Locations (1)

78229

RECRUITING

Glenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases, San Antonio

All Listed Sponsors
collaborator

Alzheimer's Association

OTHER

lead

The University of Texas Health Science Center at San Antonio

OTHER